All participants will be in listen-only mode. [Operator instructions] Please note that there will not be a Q&A session ...

Net loss was $12.8 million, or $0.36 per diluted share, in the fourth quarter of 2024 compared to a net loss of $31.1 million, or $0.67 per diluted share, in the fourth quarter of 2023. Adjusted ...

While Adobe beat on the top- and bottom-line for its fiscal first quarter and gave solid fiscal Q2 guidance, its net new ...

USA Rare Earth has a unique opportunity to become the leading domestic supplier of rare earth neo magnets and heavy rare earths required for technologies across a wide range of industries, including ...

New Investment Led by M-Cor Capital, LLC and Fortress Investment GroupExisting 10% Senior Secured Notes to be RedeemedRESTON, Va., March 12, ...

Berry Corporation (bry) (NASDAQ: BRY) (“Berry” or the “Company”) today announced financial and operating results for the fourth quarter and full year 2024, as well as a quarterly cash dividend of ...

The release of our first S-K 1300 report for Tanbreez is a significant milestone for Critical Metals Corp as we are quickly advancing the development strategy for this game-changing rare earth deposit ...

Zycus, a global leader in AI-powered procurement solutions, has marked a historic moment in procurement technology with the ...

Bernstein analyst David Vernon raised the firm’s price target on Southwest (LUV) to $33 from $31 and keeps a Market Perform rating on the ...

Gaia posted double-digit year-over-year revenue growth, driven in part by an increase in the streaming video provider’s ...

OnKure's drug candidate pipeline is highlighted by OKI-219, a selective PI3K alpha H1047R inhibitor for the treatment of certain types of breast cancer that began clinical trials in February 2024.

The investment will be executed through the direct purchase of approx. 5.8% of Eye-Net’s ordinary shares. Eye-Net granted the investors certain antidilution protections in the event of a down round ...